- Trial phase
- Phase 1 (discontinued)
- Time to market
- The program has been discontinued. No path to market exists under Caribou's current plans, though the company is exploring strategic alternatives (sale, merger, or dissolution) that could theoretically see the asset developed by another party.
- Why 2/10
- vispa-cel has been discontinued by Caribou. The only remaining catalyst is the ASH 2026 presentations (December 12-15), which are data readouts from a halted program and do not represent a binary decision point. The company's value driver is now the strategic alternatives process (sale/merger/dissolution), not this drug. ImpactScore is 2 because the drug has no scheduled binary catalyst and the program is terminated.
vispa-cel is a discontinued program at a company pursuing a fire sale or dissolution. The ASH presentations December 12-15 are the last scheduled data readouts but come from a halted program. The stock's fate now hinges entirely on the strategic alternatives process (merger, asset sale, or liquidation), not on vispa-cel data. Watch for any definitive agreement announcement from Caribou's advisor Wedbush Securities.
Price Chart
Executive Summary
vispa-cel (vispacabtagene regedleucel, formerly CB-010) is an allogeneic anti-CD19 CAR-T cell therapy that Caribou Biosciences was developing for relapsed/refractory B-cell non-Hodgkin lymphoma. Phase 1 ANTLER trial data showed promising efficacy on par with approved autologous CAR-T therapies, and the FDA granted Orphan Drug and Fast Track designations. However, on October 6, 2026, Caribou announced it was discontinuing both vispa-cel and its other CAR-T program, cutting its workforce, and exploring strategic alternatives including a potential sale or dissolution. The stock has fallen roughly 63% since the announcement to around $0.44, with a market cap of approximately $49M. The company held $94.8M in cash as of September 30, 2026. ASH 2026 presentations in December will be the final data readouts from the now-halted program.
How It Works
vispa-cel is an allogeneic (off-the-shelf, donor-derived) CAR-T cell therapy that targets the CD19 protein on cancerous B cells. It is engineered using CRISPR genome editing to make donor cells less likely to attack the patient's body and more resistant to being rejected, allowing it to be given to many patients from a single donor batch rather than requiring each patient's own cells to be harvested and re-engineered.
Trial Status
vispa-cel was being studied in the Phase 1 ANTLER trial for relapsed/refractory B-cell non-Hodgkin lymphoma. Positive data were presented at EHA in June 2026 showing a median progression-free survival of 17.1 months, with the CEO calling the program "pivotal-ready." However, on October 6, 2026, Caribou announced it was discontinuing all development of vispa-cel and its other CAR-T program CB-011, citing a challenging financing environment that has shifted investor preference toward in vivo approaches over donor-derived cell therapies.
The Two-Sided Case
Upcoming Catalysts
- ASH 2026 Annual Meeting (December 12-15, 2026): Two oral presentations and one poster on vispa-cel and CB-011 data, though these abstracts predate the program discontinuation and represent final data readouts from a halted program.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Caribou Biosciences, Inc. 8-K CRBU ·Originating report